Small Cap Feast

19th June 2024

Dish of the day
No Joiners today
Off the menu
No leavers today

Dish Of The Day:



MC Mining (MCM.L) has left AIM.

Whats baking in the oven?

Potential**** Initial Public Offerings:

ITF announced:

Media speculation: (We remove rumours after 10 days of being on the menu)

17 June 2024 -IntelliAM, an artificial intelligence company focused on the consumer goods industry, is preparing to list on Aquis in July. The Company is looking to raise roughly £5m to fund the Company’s expansion.

19th June 2024: Pri0r1ty AI, a software company, pending regulatory clearance, is expecting to raise at least £600,000 in a public listing on the Aquis Exchange in early July to launch its product

Reverse Takeovers:

Change of Market:

Dual Listing :

Banquet Buffet

Alliance Pharma 38.4p £191.8m (APH.L)

The international healthcare Company announces its preliminary results for the year ended 31 December 2023. The free cash flow was £21.3m (2022: £15.8m), which is a 35% increase. The underlying PBT increased 4% to £31.5m (2022: £30.3m) and the reported loss before tax was £48.8m (2022 restated: £23.1m loss). In 2024, the Company will continue to increase investment in sales, marketing and innovation to maintain its brand leadership position in key categories. The Board continues to anticipate that profits in FY 2024 will be in-line with FY 2023 with identified organic growth opportunities and continuous investment.

Avingtrans 410p £127.4m (AVG.L)

The Company that designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, announces a trading update for the financial year ended 31 May 2024. Revenue from continuing operations has reached a record level and is in line with market expectations. Adjusted EBITDA from continuing operations is materially ahead of market expectations and is expected to be in the range of £13-14m, partly part due to lower than budgeted commercialisation costs in the Medical Division, some of which have been delayed in to FY25. Net debt was £6.1m and was better than anticipated, with the completion of several key projects contributing to enhance cash receipts and lower-than-expected spending on medical developments.

IXICO 7.5p £3.1m (IXI.L)

The precision analytics Company delivering intelligent insights in neuroscience announces that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under five years and is worth in excess of £1m.

Light Science Technologies Holdings 2.9p £8.5m (LST.L)

The Company that focuses on addressing global challenges related to food security, climate change, and fire protection announces an initial contract with a new blue-chip customer worth in excess of £750,000, for its passive fire protection division. The contract, with a blue-chip world leader in the construction sector, which is active in more than 120 countries, involves LSTH IFB installing the Injectaclad cavity sealant throughout an 11-storey student accommodation block in Nottingham. Work on the contract has now commenced and is expected to run until December 2024, with revenues being recognised in H2 of the current financial year.

LPA Group 68p £9.0m (LPA.L)

The innovation-led engineering specialist in electronic and electro-mechanical components and systems announces its results for the six months to 31 March 2024. Revenue was £11.6m (6 months to 31 Mar 23: £9.1m), the loss before tax was £0.4m (6 months to 31 Mar 23: £0.6m) and the free cash flow is £1.5m (6 months to 31 Mar 23: £1.5m). The Group expects to deliver results for the full year in line with current market expectations even having announced delays on certain rail contracts which makes the outlook for the rest of 2024 quite challenging.

Maintel Holdings 250p £35.9m (MAI.L)

The leading provider of cloud, network and security managed communications services issues a trading update today. The Company has focused on strategic organic growth initiatives, successfully closed significant new contracts and has launched several product initiatives. The Company has secured three new significant contracts, which are all multi-year and represent £17.8m total contract value. The sales pipeline remains buoyant and cost control and working capital management is being kept in clear focus and the board is cautiously optimistic about delivering against market expectations.

Petro Matad 3.6p £39.5m (MATD.L)

The Company that focusses on oil exploration, as well as future development and production in Mongolia announces its audited final results for the year ended 31 December 2023. The cash position was $4.5m (31 December 2022: $5.1m) and the net loss after tax was $5.9m (31 December 2022: loss $2.95m). The Company is optimistic that its successful applications for two new areas, Block XX and Block V, will see the blocks awarded in late 2024 or early 2025.

SEED Innovations 2.0p £3.67 m (SEED.L)

The investment Company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors announce its Final Results for the year ended 31 March 2024. The cash position was strong with approximately £3.9m at the date of this announcement. The comprehensive loss was £2.1m (2023: £4522m). Shares are currently trading at c.70% discount to 31 March 2024 NAV. The Company’s board remains optimistic about SEED's current investment portfolio, expecting to make a good allocation of the strong cash flow by taking advantage of historically low prices of the investment opportunity in the sector the Company is focused on.

Steppe Cement 19p £39.4m (STCM .L)

The investment holding Company that engages in the production and sale of cement and clinkers in Kazakhstan today announces the final results for the year ended 31 December 2023. The Company’s revenue was USD81.8m (2022: 86.7m), a slight fall due to increasing competition in the local market. And the net profit was USD4.5m (2022: USD17.9m), due to the increase in cost of production by USD8m due to the inflationary environment. The Company has plans for a further USD2.4m investment in 2024.

Young & Co's Brewery 976p £375.7m (YNGA .L)

The Company that engages in the operation and management of pubs and hotels in the UK, today announces its unaudited results for the 52 weeks ended 1 April 2024. Total revenue increased 7.4% to £388.8m and on a like-for like 52-week basis was up 3.4% against strong results in 2023. Adjusted profit before tax grew by 9.3% to a record £49.4m for the period, despite the impact of continued cost inflation. The recent investments, acquisitions and City Pub Group transaction provide good long-term growth potential along with the upcoming series of sports events in the summer.


19 June 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram